Search clinical trials for: Advanced Hematologic Malignancies

Total 39061 results

Constellation Pharmaceuticals

Not yet recruiting

An Extension Study for Patients Previously Enrolled in Studies With Pelabresib

Solid Tumor | Hematologic Malignancy | Advanced Malignancies
Shanghai Yuyao Biotech Co., Ltd.

Recruiting

An Open-Label, Multicenter, Phase I Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of YY201 in Patients With Advanced Solid Tumors and Hematological Malignancies

Advanced Solid Tumor | Hematological Malignancy

China
Hangzhou DAC Biotechnology Co., Ltd.

Not yet recruiting

A Study of DXC006 in Patients With Advanced Solid Tumors and Hematologic Malignancies

Advanced Solid Tumors | Hematological Malignancies
Nanjing Chia-tai Tianqing Pharmaceutical

Recruiting

A Phase 1 Clinical Trail of NTQ2494 Tablets in Patients With Advanced Hematological Malignancies

Relapsed/Refractory Acute Myeloid Leukemia (AML)

China
Vincerx Pharma, Inc.

Recruiting

Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies

Acute Myeloid Leukemia | B-cell Acute Lymphoblastic Leukemia | High-risk Myelodysplastic Syndrome

United States
Kymera Therapeutics, Inc.

Recruiting

Safety and Clinical Activity of KT-253 in Adult Patients With High Grade Myeloid Malignancies, Acute Lymphocytic Leukemia, Lymphoma, Solid Tumors

Advanced Solid Tumors | Acute Lymphocytic Leukemia | Lymphomas | Myeloid Malignancies

United States
Westlake Therapeutics

Recruiting

Safety, Tolerability and Preliminary Efficacy of Engineered Red Blood Cell in Patients With Advanced Malignancies (Reboot-101)

Cancer | Solid Tumor | Hematologic Malignancy

China
H. Lee Moffitt Cancer Center and Research Institute
Precigen, Inc

Recruiting

Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor Malignancies

Acute Lymphoblastic Leukemia | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Diffuse Large B Cell Lymphoma | Triple Negative Breast Cancer Malignancies

United States
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

Safety, Tolerability, Pharmacokinetic Characteristics, and Efficacy of CM369 in Advanced Solid Tumors & Hematologic Malignancies

Advanced Solid Tumors and Hematologic Malignancies

China
Blueprint Medicines Corporation

Recruiting

Study of Elenestinib (BLU-263) in Advanced Systemic Mastocytosis (AdvSM) and and Other KIT Altered Hematologic Malignancies (AZURE)

Advanced Systemic Mastocytosis

United States, Norway, Netherlands, Belgium, Germany, France, Spain
University College, London

Not yet recruiting

Allogeneic T Cells Expressing T Cell Receptor-KDEL and the Chimeric Antigen Receptor CAT19 for the Treatment of Advanced CD19+ Malignancies (KCAT19)

Blood Cancer
Chimagen Biosciences, Ltd

Recruiting

First-in-Human (FIH) Trial of 1A46 in Subjects With Advanced CD20 and/or CD19 Positive B-cell Hematologic Malignancies

Non-Hodgkin's Lymphoma (Disorder) | Acute Lymphoid Leukemia, Disease (Disorder)

United States
Antengene Discovery Limited

Recruiting

A Study of ATG-018 (ATR Inhibitor) Treatment in Patients With Advanced Solid Tumors and Hematological Malignancies (ATRIUM)

Advanced Solid Tumors | Hematological Malignancies

Australia
Helsinki University Central Hospital

Recruiting

The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs (FINPROVE)

Solid Tumor | Advanced Cancer | Haematological Malignancy

Finland
Stanford University
Orca Biosystems, Inc.

Recruiting

Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft

Myelodysplastic Syndromes | Myeloproliferative Disorders | Acute Leukemia | Chronic Myelogenous Leukemia | Allogeneic Hematopoietic Cell Transplantation (HCT) | Advanced Hematologic Malignancies

United States
Curon Biopharmaceutical (Australia) Co Pty Ltd
Novotech (Australia) Pty Limited

Not yet recruiting

A Study of CN202 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors or Hematologic Malignancies

Metastatic Solid Tumor | Hematologic Malignancies | Locally Advanced Solid Tumor
Suzhou Junjing BioSciences Co., Ltd.

Recruiting

The Safety and Efficacy of Multiple-dose of WJ01024 in Subject With Advanced Cancer

Advanced Solid Tumors | Advanced Hematologic Malignancies

China
Foghorn Therapeutics Inc.

Recruiting

FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic Malignancies

Refractory Acute Myeloid Leukemia | Refractory Chronic Myelomonocytic Leukemia | Relapsed Acute Myeloid Leukemia | Relapsed Myelodysplastic Syndromes | Refractory Myelodysplastic Syndromes | Advanced Hematologic Malignancy | Relapsed Chronic Myelomonocytic Leukemia

United States
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Not yet recruiting

Phase 1 Trial of the TQB2928 Injection in Patients With Advanced Cancers

Advanced Solid Tumors and Hematological Malignancies
Hutchmed

Recruiting

A Study of HMPL-306 in Advanced Hematological Malignancies With mIDH

Isocitrate Dehydrogenase Gene Mutation

Spain, United States
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Anhui Provincial Hospital

Recruiting

CAR-T CD19/CD20 for Patients With Advanced CD19/CD20+ B Cell Line Recurrent or Refractory Hematological Malignancies

CAR

China
Medical University of Vienna
Roche Pharma AG; Allcyte GmbH

Recruiting

Comprehensive Genomic Profiling and Next Generation Functional Drug Screening for Patients With Aggressive Haematological Malignancies (EXALT-2)

Refractory Acute Myeloid Leukemia | Advanced Lymphoma | Refractory Lymphoma | Refractory Leukemia | Refractory T-Cell Lymphoma

Austria
Compugen Ltd

Recruiting

COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies

Multiple Myeloma | Ovarian Cancer | Lung Cancer | Advanced Cancer | Colon Cancer | Plasma Cell Neoplasm | HNSCC | Microsatellite Stable Colorectal Carcinoma | MSS-CRC

United States
Institut Cancerologie de l'Ouest

Recruiting

Impact of the Coordinated Intervention of the Healthcare Facilities Pharmacist and the Dispensary Pharmacist on the Care Pathway for Cancer Patients Treated With Oral Therapy (IPPACTTO)

Relapsed Hematologic Malignancy | Advanced or Metastatic Solid Tumor

France
Antengene Therapeutics Limited
Bristol-Myers Squibb

Recruiting

Safety and Preliminary Efficacy of ATG-017 Monotherapy or Combination Therapy With Nivolumab in Advanced Solid Tumors and Hematological Malignancies (ERASER)

Solid Tumor | Hematological Malignancy

Australia
Bio-Path Holdings, Inc.

Recruiting

A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies

Follicular Lymphoma | Hodgkin Lymphoma | Waldenstrom Macroglobulinemia | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Lymphoma (SLL) | DLBCL | Cutaneous T-cell Lymphoma (CTCL) | Peripheral T-cell Lymphoma (PTCL)

United States
Merck Sharp & Dohme LLC

Recruiting

Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

Solid Tumors | Hematologic Malignancies

United States, Poland, Brazil, Ukraine, Argentina, Australia, Austria, Belgium, Canada, Chile, China, Colombia, Czechia, Denmark, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Israel, Italy, Japan, Korea, Republic... and more
Ascentage Pharma Group Inc.

Recruiting

APG-1387 in Patients With Advanced Solid Tumors or Hematologic Malignancies

Advanced Solid Tumors or Hematologic Malignancies

United States
Institut Bergonié

Recruiting

Bergonie Institut Profiling : Fighting Cancer by Matching Molecular Alterations and Drugs in Early Phase Trials (BIP)

Solid Tumor | Hematological Malignancy

France
Institut de Recherches Internationales Servier

Recruiting

Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation

Myelodysplastic Syndromes | Relapsed or Refractory Acute Myeloid Leukemia (AML) | Untreated AML | Other IDH1-mutated Positive Hematologic Malignancies

United States, France
Sutro Biopharma, Inc.

Completed

Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies

Follicular Lymphoma | B-cell Lymphoma | Multiple Myeloma | Mantle Cell Lymphoma | Non Hodgkin Lymphoma | Diffuse Large B Cell Lymphoma | Indolent Lymphoma | B Cells--Tumors

United States
UNICANCER
Hoffmann-La Roche; National Cancer Institute, France; Fondation ARC

Active, not recruiting

Phase 2 Study Assessing Secured Access to Vemurafenib for Patients With Tumors Harboring BRAF Genomic Alterations (AcSé)

Solid Tumors | Hematologic Cancers | Metastatic Cancers

France
Arcus Biosciences, Inc.
Gilead Sciences

Active, not recruiting

A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies (ARC-12)

Melanoma | Lymphoma, Non-Hodgkin | Cervical Cancer | Multiple Myeloma | Gastric Cancer | Esophageal Cancer | Advanced Solid Tumor | Gastroesophageal Junction Adenocarcinoma | Non Small Cell Lung Cancer (NSCLC) | Diffuse Large B Cell Lymphoma (DLBCL)

United States, Spain, Poland
Eli Lilly and Company
Loxo Oncology, Inc.

Active, not recruiting

Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations

Acute Myeloid Leukemia (AML) | Chronic Myelomonocytic Leukemia (CMML) | Myelodysplastic Syndrome (MDS) | Myeloproliferative Neoplasms (MPNs)

United States, Spain, Korea, Republic of, France, Taiwan, Australia, Belgium, Singapore, Israel, Canada, Germany, Finland
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Hu8F4 in Treating Patients With Advanced Hematologic Malignancies

Hematopoietic and Lymphoid Cell Neoplasm | Myelofibrosis | Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Secondary Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Recurrent Chronic Myelomonocytic Leukemia | Refractory Chronic Myelomonocytic Leukemia | High Risk... and other conditions

United States
AstraZeneca

Terminated

Study of AZD0466 Monotherapy or in Combination in Patients With Advanced Haematological Malignancies

Haematological Malignancies

France, Italy, United States, Korea, Republic of, Germany, Australia
M.D. Anderson Cancer Center
Incyte Corporation

Completed

INCB018424 in Patients With Advanced Hematologic Malignancies

Acute Myeloid Leukemia | Myelodysplastic Syndrome | Acute Lymphocytic Leukemia | Chronic Myelogenous Leukemia

United States
Celldex Therapeutics
Merck Sharp & Dohme LLC

Completed

A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies

Melanoma | Follicular Lymphoma | Renal Cell Carcinoma | Breast Cancer | Head and Neck Cancer | Gastric Cancer | Colorectal Cancer | Esophageal Cancer | Pancreatic Adenocarcinoma | Ovarian Cancer | Fallopian Tube Cancer | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Lymphoplasmacytic Lymphoma | Non-Hodgkin Lymphoma | ... and other conditions

United States
M.D. Anderson Cancer Center

Active, not recruiting

Distress Associated With Coronavirus Disease 2019 and Telehealth on Supportive Care Patients With Advanced Cancer

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Malignant Solid Neoplasm | Locally Advanced Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | COVID-19 Infection | Recurrent Hematologic Malignancy

United States
Epizyme, Inc.
Celgene

Completed

A Phase 1, Open-Label, Dose-Escalation & Expanded Cohort, Continuous IV Infusion, Multi-center Study of the Safety, Tolerability,PK & PD of EPZ-5676 in Treatment Relapsed/Refractory Patients With Leukemias Involving

Acute Myeloid Leukemia | Myeloproliferative Disorders | Acute Lymphoblastic Leukemia | Myelodysplastic Syndrome

United States, Germany, Netherlands
AstraZeneca
Parexel

Active, not recruiting

AZD4573 in Novel Combinations With Anti-cancer Agents in Patients With Advanced Blood Cancer

Advanced Haematological Malignancies

Spain, United States, Canada, Korea, Republic of, Poland, Australia, France, United Kingdom, Ireland
Actuate Therapeutics Inc.

Active, not recruiting

9-ING-41 in Patients With Advanced Cancers

Sarcoma | Cancer | Breast Neoplasms | Neoplasm Metastasis | Pancreatic Neoplasms | Pancreatic Cancer | Pancreatic Adenocarcinoma | Bone Cancer | Malignant Glioma | Bone Metastases | Pancreas Cancer | Renal Cancer | Refractory Non-Hodgkin Lymphoma | Bone Neoplasm | Neoplasm, Breast | Refractory Cancer | Refractory Neoplasm | Resistant... and other conditions

United States, Belgium, Canada, Spain, France, Netherlands, Portugal
Constellation Pharmaceuticals

Completed

Study Evaluating Food Effect and QTc in Patients With Advanced Malignancies

Solid Tumor | Advanced Malignancies | Hematological Malignancy

Spain, United States, Georgia
OHSU Knight Cancer Institute
Oregon Health and Science University

Terminated

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Primary Myelofibrosis | Anemia | Recurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Anatomic Stage IV Breast Cancer AJCC v8 | Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Chronic Myelomonocytic Leukemia | Refractory Myelodysplastic... and other conditions

United States
UNICANCER
Pfizer; National Cancer Institute, France; Fondation ARC

Completed

Phase 2 Study Assessing Efficacy and Safety of Crizotinib in Patients Harboring an Alteration on ALK, MET or ROS1 (AcSé)

Metastatic Cancer | Solid Tumors | Hematologic Cancers

France
Boryung Pharmaceutical Co., Ltd

Active, not recruiting

BR101801 in Adult Patients With Advanced Hematologic Malignancies( Phase I)

Follicular Lymphoma | B Cell Lymphoma | Waldenstrom Macroglobulinemia | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Diffuse Large B Cell Lymphoma | Peripheral T Cell Lymphoma | Small Lymphocytic Leukemia

Korea, Republic of, United States
Celgene
Agios Pharmaceuticals, Inc.

Completed

Phase 1/2 Study of Enasidenib (AG-221) in Adults With Advanced Hematologic Malignancies With an Isocitrate Dehydrogenase Isoform 2 (IDH2) Mutation

Hematologic Neoplasms

United States, France
Cellestia Biotech AG

Terminated

Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies

Breast Cancer | Adenoid Cystic Carcinoma | Hepatocellular Carcinoma | Colorectal Cancer | Osteosarcoma | Non-hodgkin Lymphoma | Glomus Tumor, Malignant | T-ALL

United States, Spain, Korea, Republic of, Germany, France, Switzerland
Pfizer

Active, not recruiting

A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma

Lymphoma | Diffuse Large B-Cell Lymphoma | Acute Myeloid Leukemia | Multiple Myeloma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies

Recurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Recurrent B Acute Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia | Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Systemic Mastocytosis | Recurrent... and other conditions

United States

Search clinical trials for: Advanced Hematologic Malignancies

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Lithuania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations